The following is an excerpt. To view the full article please visit the link below.

Senior fellow Richard Gold weighs in on the updated terms for new NAFTA that puts hold on potential price increases for some drugs. Final terms in the trade deal that the U.S. agreed to on Tuesday remove a provision that would have increased protections to 10 years around a generally more expensive category of drugs called biologics.

The extra years of protection would have added significant costs to the health-care system, private drug plans, and to those paying alone, said Richard Gold, a law professor at McGill University and senior fellow at the Centre for International Governance Innovation.

"Two years of extra...

* * *
The opinions expressed in this article/multimedia are those of the author(s) and do not necessarily reflect the views of CIGI or its Board of Directors.